These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2092238)

  • 21. The pill and gynecologic cancer: controversy and mystery prevail.
    Sargent MA
    J Med Assoc Ga; 1995 Sep; 84(7):320-2. PubMed ID: 7561539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population-based cancer screening.
    Champion VL; Rawl SM; Menon U
    Oncol Nurs Forum; 2002 Jun; 29(5):853-61. PubMed ID: 12058160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gynaecological cancers in Umbria (Italy): trends of incidence, mortality and survival, 1978-1998.
    Minelli L; Stracci F; Prandini S; Moffa IF; La Rosa F
    Eur J Obstet Gynecol Reprod Biol; 2004 Jul; 115(1):59-65. PubMed ID: 15223167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Organization of prophylactic gynecologic exams with mass cytological screening of women].
    Buval'tseva NA; Kvashenko BK
    Pediatr Akus Ginekol; 1978; (3):35-6. PubMed ID: 673514
    [No Abstract]   [Full Text] [Related]  

  • 25. [Methodologic and organizational principles of selective screening for cervical, endometrial and ovarian carcinoma].
    Zalutskiĭ IV; Vishnevskaia EE; Kurian LM
    Vopr Onkol; 2006; 52(1):74-7. PubMed ID: 16715709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cancer-prevention examinations in the woman].
    Stoll P
    Fortschr Med; 1974 Mar; 92(9):369-72. PubMed ID: 4819505
    [No Abstract]   [Full Text] [Related]  

  • 27. [Our responsibility in the field of gynecologic cancer].
    Dolhay B; Jakubecz S; Papp Z; Herpay G; Gardó S
    Orv Hetil; 1968 Dec; 109(5):2821-5. PubMed ID: 5717809
    [No Abstract]   [Full Text] [Related]  

  • 28. [Problem of uterine and ovarian cancer mass screening].
    Ohmura M; Oda M
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1907-16. PubMed ID: 12465389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gynecologic cancers: Part. II--risk assessment and screening.
    Lee CO
    Clin J Oncol Nurs; 2000; 4(2):73-7. PubMed ID: 11107379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology and screening of ovarian cancer.
    Tortolero-Luna G; Mitchell MF; Rhodes-Morris HE
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):1-23. PubMed ID: 8015758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An analysis of the prevalence and incidence of gynecologic cancer cytologically detected in a population of 175,767 women.
    Kasper TA; Smith ES; Cooper P; Clayton J; Todd D
    Acta Cytol; 1970 May; 14(5):261-9. PubMed ID: 5284264
    [No Abstract]   [Full Text] [Related]  

  • 32. Social inequality and incidence of and survival from cancer of the female genital organs in a population-based study in Denmark, 1994-2003.
    Jensen KE; Hannibal CG; Nielsen A; Jensen A; Nøhr B; Munk C; Kjaer SK
    Eur J Cancer; 2008 Sep; 44(14):2003-17. PubMed ID: 18662869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Gynecologic cytological cancer screening over an 11-year period].
    Kasabova M; Ganchev I
    Akush Ginekol (Sofiia); 1990; 29(3):55-9. PubMed ID: 2252150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mass screening against endometrial carcinoma].
    Salvesen HB
    Tidsskr Nor Laegeforen; 2002 Aug; 122(18):1774-6. PubMed ID: 12362687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
    Hutchinson ML; Berger BM; Farber FL
    Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A model of the prevention of malignant female genital neoplasms introduced into the gynecological health services in the Bialystok macroregion].
    Soszka S; Kazanowska W; Knapp P
    Probl Med Wieku Rozwoj; 1983; 12():220-6. PubMed ID: 6674975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
    Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER
    Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [On a mass screening survey for gynecologic carcinomata in a rural community].
    Montanari GR; Grismondi GL; Marconato A; Gioia E; Montanari GD
    Attual Ostet Ginecol; 1968; 14(5):413-5. PubMed ID: 5737605
    [No Abstract]   [Full Text] [Related]  

  • 40. Colorectal cancer in women: an equal opportunity disease.
    Osias GL; Osias KB; Srinivasan R
    J Am Osteopath Assoc; 2001 Dec; 101(12 Suppl Pt 2):S7-12. PubMed ID: 11794751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.